|
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate, gemcabene (CI-1027 licensed from Pfizer in 2011), as add-on to the standard of care especially statins that will benefit patients, physicians, and payors.
SOCIAL MEDIA:
Website: http://www.gemphire.com/index.php
LOCATION:
17199 N. Laurel Park Dr., Suite 401 Livonia, MI 48152
PEOPLE:
CEO (interim): Mr. Steve Gullans
|
IN THE NEWS
|
|
|
|
